SAN DIEGO, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc . (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today